MEANTI RAMONA

Bassi, G., Giorgi, V., Lazzarin, M., Meanti, R., Omeljaniuk, R., Sarzi-Puttini, P., et al. (2025). Symptom management, adherence to therapy, and filling the gaps of medical cannabis therapy: a qualitative study on the importance of nursing consultations for fibromyalgia patients. JOURNAL OF CANNABIS RESEARCH, 7(1) [10.1186/s42238-025-00346-z]. Dettaglio

Costanzi, E., Grisetti, M., Bettucci, M., Meanti, R., Lonati, E., Morello, G., et al. (2025). Exploring the role of mesenchymal stem cell-derived extracellular vesicles in Alzheimer's disease: the impact of MSC preconditioning on targeted therapeutic efficacy. Intervento presentato a: ISEV2025 Annual Meeting, Vienna. Dettaglio

Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R., et al. (2025). Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases. BIOMÉDECINE & PHARMACOTHÉRAPIE, 186(May 2025) [10.1016/j.biopha.2025.118044]. Dettaglio

Mingardi, J., Meanti, R., Paoli, C., Cifani, C., Torsello, A., Popoli, M., et al. (2025). Ghrelin, Neuroinflammation, Oxidative Stress, and Mood Disorders: What Are the Connections?. CURRENT NEUROPHARMACOLOGY, 23(2), 172-186 [10.2174/1570159x22999240722095039]. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Potential application of Growth Hormone Secretagogues (GHS) for Amyotrophic Lateral Sclerosis (ALS) treatment: mechanisms of action and neuroprotective effects characterization in human SH-SY5Y SOD1G93A cells. Intervento presentato a: Innovazione e malattie rare: dalla ricerca preclinica al paziente, Bari, Italia. Dettaglio